Viyash has ten manufacturing facilities in India with a combined capacity of 2000 KL as well as one formulation facility in the US, and is now one of India’s leading mid-tier integrated API and formulation players
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
Expands wound care portfolio and aims to drive greater market penetration and availability in the wound dressing category
The first clinical trial is expected to commence in early 2022 both in Europe and the US
If approved, Gavreto will be the first and only targeted treatment approved by the EMA that includes first-line treatment of people with RET fusion-positive advanced NSCLC
The net proceeds from the issue will be utilised towards the purchase of machinery, modernising existing units and expansion of its R&D facilities
The division will focus on products that are required during ophthalmic surgical procedures like cataracts and refractive surgeries among others
The focus is on wellness and personal care products
The bioequivalence study was conducted by Accutest Research India, one of the preferred CRO players in India
This is Omeza’s first Rx product and the first drug/device combination matrix of its kind for chronic wound care
Subscribe To Our Newsletter & Stay Updated
